| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6268489 | PF PRISM CV | Azithromycin dihydrate |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6068859 | PF PRISM CV | Controlled-release dosage forms of Azithromycin |
May, 2017
(6 years ago) | |
| US6984403 | PF PRISM CV | Azithromycin dosage forms with reduced side effects |
Feb, 2024
(2 months ago) | |
| US7887844 | PF PRISM CV | Multiparticulate crystalline drug compositions having controlled release profiles |
Feb, 2024
(2 months ago) | |
Zmax is owned by Pf Prism Cv.
Zmax contains Azithromycin.
Zmax has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Zmax are:
- US6068859
- US6984403
- US7887844
- US6268489
Zmax was authorised for market use on 10 June, 2005.
Zmax is available in for suspension, extended release;oral dosage forms.
Zmax can be used as method of treating bacterial infections.
The generics of Zmax are possible to be released after 14 February, 2024.
Drugs and Companies using AZITHROMYCIN ingredient
Market Authorisation Date: 10 June, 2005
Treatment: Method of treating bacterial infections
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
More Information on Dosage
ZMAX family patents
